Deutsche Märkte öffnen in 2 Stunden 56 Minuten

Bristol-Myers Squibb Company (BMY)

NYSE - NYSE Verzögerter Preis. Währung in USD
Zur Watchlist hinzufügen
40,81-0,16 (-0,39%)
Börsenschluss: 04:00PM EDT
40,88 +0,07 (+0,17%)
Nachbörse: 07:58PM EDT

Bristol-Myers Squibb Company

Route 206 & Province Line Road
Princeton, NJ 08543
United States
609 252 4621

BrancheDrug Manufacturers - General

Leitende Angestellte

Dr. Christopher S. Boerner Ph.D.CEO & Chairman3,14MN/A1971
Mr. David V. ElkinsExecutive VP & CFO2,28MN/A1968
Ms. Sandra Leung Esq.Executive VP & General Counsel2,58MN/A1961
Mr. Samit Hirawat M.D.Executive VP, Chief Medical Officer & Head of Development2,62MN/A1969
Mr. Greg MeyersExecutive VP and Chief Digital & Technology OfficerN/AN/A1973
Mr. Timothy PowerVP & Head of Investor RelationsN/AN/AN/A
Ms. Kimberly M. JablonskiChief Compliance & Ethics OfficerN/AN/AN/A
Ms. Ahn Amanda PooleExecutive Vice President & Chief Human Resources OfficerN/AN/A1975
Dr. Joseph J. Eiden Jr.Head of Medical AffairsN/AN/A1949
Mr. Adam LenkowskyExecutive VP, Chief Commercialization Officer & Head of U.S. OncologyN/AN/A1972
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.


Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Corporate Governance

Bristol-Myers Squibb Companys ISS Governance QualityScore, Stand 1. Juni 2024, lautet 4. Die grundlegenden Scores sind Audit: 9, Vorstand: 7, Shareholderrechte: 2, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.